MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine
- Newly appointed CMO with more than 25 years’ experience in vaccine development
- Fast Track status granted by US Food and Drug Administration
- Completion of enrolment of its 2nd phase II clinical trial in pregnant women
Copenhagen, Denmark, 5 January 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.